olmesartan has been researched along with Albuminuria in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (14.89) | 29.6817 |
| 2010's | 39 (82.98) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Chatzikyrkou, C; Haller, H; Korda, A; Menne, JJ; Scurt, FG | 1 |
| Chatzikyrkou, C; Haller, H; Izzo, J; Menne, J; Mertens, PR; Rabelink, T; Ruilope, LM; Rump, C; Viberti, G | 1 |
| Hirooka, Y; Nishihara, M; Takesue, K | 1 |
| Ichikawa, H; Kimura, Y; Narita, I; Narita, M; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H; Yokono, Y | 1 |
| Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M | 1 |
| Daikuhara, H; Fukunaga, K; Ohshima, T | 1 |
| Halleck, F; Holleck-Weithmann, S; Kossmehl, P; Kreutz, R; Rothermund, L; Schröder, K | 1 |
| Chin, HJ; Choi, BS; Hwang, JH; Kim, DK; Kim, S; Lee, SH; Lim, CS; Park, JH; Shin, SJ | 1 |
| Ahn, SY; Bae, E; Chin, HJ; Choi, BS; Han, SS; Kim, DK; Kim, S; Lee, SH; Lim, CS; Park, JH; Shin, SJ | 1 |
| Böhm, M; Bramlage, P; Haller, H; Ruilope, LM; Schmieder, RE | 1 |
| Chen, J; Chen, M; Gu, J; He, L; Hu, H; Jing, Y; Li, L; Mei, C; Mei, S; Qi, N; Song, S; Sun, L; Wu, M; Wüthrich, RP; Yang, M | 1 |
| Hashimoto, K; Horino, T; Inoue, K; Iwasaki, Y; Kagawa, T; Matsumoto, R; Morita, T; Taguchi, T; Takao, T; Terada, Y | 1 |
| Hamamoto, Y; Honjo, S; Ikeda, H; Koshiyama, H; Nabe, K; Wada, Y | 1 |
| García De La Villa, B; Tofé Povedano, S | 1 |
| Akabane, T; Ishimitsu, T; Masuda, T; Matsuoka, H; Minami, J; Numabe, A; Okamura, A | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, AJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC | 1 |
| Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S | 1 |
| Bakris, G; Haller, H; Izzo, J; Oparil, S; Ruilope, L; Sowers, J; Waeber, B; Weber, M | 1 |
| Chen, R; Eisner, C; Hu, X; Huang, Y; Kopp, JB; Leelahavanichkul, A; Mizel, D; Schnermann, J; Star, RA; Wright, EC; Yan, Q; Yuen, PS; Zhou, H | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Shimada, K | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Ingelfinger, JR | 1 |
| Palatini, P | 1 |
| Ritz, E | 1 |
| de Zeeuw, D; Heerspink, HJ; Roscioni, SS | 1 |
| Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T | 1 |
| Aessopos, A; Farmakis, D | 1 |
| Fioretto, P; Mauer, M | 1 |
| Krämer, BK; Krüger, B; Lammert, A | 1 |
| Lehman, R; Yudkin, JS | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Hayashi, K | 1 |
| Cohen, DL; Townsend, RR | 1 |
| Cascón, JD; Consuegra-Sánchez, L; Núñez, J; Picó, F; Sanchis, J; Villegas, M | 1 |
| Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A | 1 |
| Fukuda, M; Ichikawa, T; Ito, A; Kato, Y; Kimura, G; Miura, T; Mizuno, M; Naito, T; Ono, M; Sasakawa, Y; Sato, R; Shirasawa, Y; Togawa, H; Tomonari, T; Yoshida, A | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Chatzykirkou, C; Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Hirao, K; Mikawa, T; Mori, H; Nakajima, K; Niizuma, M; Ukai, H; Umemura, S; Yamamoto, H; Yuasa, S | 1 |
| Chatzikyrkou, C; Menne, J | 1 |
| Azushima, K; Fujikawa, T; Kanaoka, T; Kobori, H; Maeda, A; Ohsawa, M; Tamura, K; Umemura, S; Wakui, H; Yanagi, M | 1 |
| Haller, H; Menne, J; Ritz, E | 1 |
| Halimi, S | 1 |
| Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Mimran, A; Rabelink, AJ; Remuzzi, G; Ritz, E; Ruilope, LM; Rump, LC; Viberti, GC | 1 |
| Ito, M; Izuhara, Y; Miyata, T; Ohtomo, S; Van Ypersele De Strihou, C | 1 |
5 review(s) available for olmesartan and Albuminuria
| Article | Year |
|---|---|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endothelium, Vascular; Humans; Imidazoles; Renin-Angiotensin System; Risk Factors; Tetrazoles | 2010 |
Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Tetrazoles | 2012 |
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Imidazoles; Incidence; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Metabolic Syndrome; Multicenter Studies as Topic; Placebos; Primary Prevention; Randomized Controlled Trials as Topic; Rats; Rats, Inbred Strains; Risk Factors; Sex Factors; Tetrazoles; Time Factors; Treatment Outcome | 2005 |
21 trial(s) available for olmesartan and Albuminuria
| Article | Year |
|---|---|
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Young Adult | 2013 |
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Telmisartan; Tetrazoles | 2014 |
Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diet, Sodium-Restricted; Female; Food; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Renal Insufficiency, Chronic; Single-Blind Method; Sodium; Sodium, Dietary; Surveys and Questionnaires; Tetrazoles | 2014 |
Urinary adiponectin and albuminuria in non-diabetic hypertensive patients: an analysis of the ESPECIAL trial.
Topics: Adiponectin; Adult; Albuminuria; Antihypertensive Agents; Creatinine; Diet Therapy; Female; Humans; Hypertension; Imidazoles; Linear Models; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Education as Topic; Tetrazoles | 2015 |
The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Imidazoles; Incidence; Male; Middle Aged; Tetrazoles | 2016 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2009 |
24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Circadian Rhythm; Creatinine; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2009 |
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Azetidinecarboxylic Acid; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Lipoproteins, LDL; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Trichlormethiazide | 2009 |
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography, Ambulatory; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imidazoles; Middle Aged; Patient Selection; Placebos; Reference Values; Tetrazoles; Young Adult | 2010 |
Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Renal Insufficiency, Chronic; Tetrazoles | 2010 |
Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Europe; Female; Humans; Hypertension; Hypoglycemic Agents; Imidazoles; Male; Middle Aged; Office Visits; Predictive Value of Tests; Regression Analysis; Risk Assessment; Risk Factors; Tetrazoles; United States; Young Adult | 2011 |
Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Dihydropyridines; Dinoprost; Diuretics; Female; Humans; Imidazoles; Male; Middle Aged; Sleep; Tetrazoles | 2011 |
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Imidazoles; Male; Middle Aged; Tetrazoles; Young Adult | 2011 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Middle Aged; Research Design; Sympatholytics; Tetrazoles | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Imidazoles; Male; Middle Aged; Prognosis; Proteinuria; Renin; Tetrazoles; Young Adult | 2012 |
Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Treatment Outcome | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardio-Renal Syndrome; Circadian Rhythm; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Treatment Outcome | 2013 |
The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Collagen Type IV; Comorbidity; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Tetrazoles | 2013 |
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Tetrazoles | 2006 |
21 other study(ies) available for olmesartan and Albuminuria
| Article | Year |
|---|---|
Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Sex Factors; Tetrazoles | 2020 |
Predictors for the development of microalbuminuria and interaction with renal function.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Imidazoles; Incidence; Kidney; Male; Middle Aged; Risk Factors; Tetrazoles; Young Adult | 2017 |
Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease.
Topics: Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Combined Modality Therapy; Heart; Hypertension; Imidazoles; Kidney; Male; Mice; Mice, Inbred ICR; Nephrectomy; Organ Size; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sympathectomy; Sympathetic Nervous System; Tetrazoles | 2019 |
Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin.
Topics: Albuminuria; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Biomarkers; Blood Pressure; Blotting, Western; Imidazoles; Male; Mice; NADPH Oxidases; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; Tetrazoles | 2018 |
Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Rats, Wistar; Receptors, Angiotensin; Renal Insufficiency; Tetrazoles | 2015 |
Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis.
Topics: Albuminuria; Angiotensin II; Animals; Apoptosis; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Imidazoles; Male; Mice; Mice, Inbred Strains; p38 Mitogen-Activated Protein Kinases; Podocytes; Sirtuin 1; Tetrazoles | 2016 |
Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylglucosaminidase; Albumins; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cells, Cultured; Deoxyguanosine; Dose-Response Relationship, Drug; Humans; Imidazoles; Kidney Tubules, Proximal; NADPH Oxidases; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Fibrosis; Genetic Predisposition to Disease; Glomerulonephritis; Heart Diseases; Hydralazine; Hypertension; Imidazoles; Infusion Pumps, Implantable; Infusions, Subcutaneous; Kidney; Kidney Diseases; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Nephrectomy; Sodium Chloride, Dietary; Species Specificity; Telemetry; Tetrazoles; Time Factors; X-Ray Microtomography | 2010 |
Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Tetrazoles | 2011 |
Reduction of albuminuria with antihypertensive treatment: is more always better?
Topics: Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Humans; Hydrochlorothiazide; Imidazoles; Tetrazoles | 2011 |
Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Imidazoles; Randomized Controlled Trials as Topic; Tetrazoles | 2011 |
Diabetes: ROADMAP: the road to renoprotection?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Treatment Outcome | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
Olmesartan, microalbuminuria, and type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; Imidazoles; Tetrazoles | 2011 |
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2011 |
"ROADMAP" controversies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Imidazoles; Prevalence; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; United States; United States Food and Drug Administration | 2011 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Hydralazine; Hydrochlorothiazide; Imidazoles; Juxtaglomerular Apparatus; Male; Membrane Proteins; Podocytes; Rats; Rats, Inbred OLETF; Reserpine; Tetrazoles | 2012 |
Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazoles; Prevalence; Randomized Controlled Trials as Topic; Tetrazoles | 2012 |
Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Imidazoles; Kidney; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Nitric Oxide Synthase Type II; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Serpins; Tetrazoles | 2008 |